Clinical trial · Observational
Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients
Transfusion-related Epstein-Barr Virus (EBV) Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients: a Multicenter Prospective Cohort Study (TREASuRE Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In many countries, numerous steps are taken to minimize the risk of infection from transfused blood products. Typically, blood banking organisations will screen for an array of infectious pathogens as part of their quality control protocol. While transmission of these tested agents via transfusion has become exceedingly rare, the risk of transfusion-transmitted infections for which testing is not currently performed continues to be a concern. Among these untested infectious agents is Epstein-Barr virus (EBV, also known as human herpesvirus-4). Most notably, infection with this virus in transplant recipients can give rise to a malignant disorder called post-transplant lymphoproliferative disease (PTLD), a life-threatening complication which is due to the uncontrolled expansion of EBV-infected cells. It is also associated with other complications such as hepatitis, hemophagocytic syndrome, etc. in transplant population. It is recognised that EBV infection can occurred in transfused immune suppressed graft recipients but the origin of the viral infection is still a matter of debate. It is a known fact that the EBV already present in the recipient's blood can undergo reactivation due to immune suppression. However, because it is known to occur more frequently in patients who are EBV-seronegative at the time of transplant, it is also accepted that primary infection contracted via an infected graft can be a source of virus. The question we are seeking to answer is whether immune suppressed graft recipients can acquire primary EBV infection via transfusion of blood products. EBV is present in the blood of most adults and cases of EBV transfusion-related infection have been reported. Transplant populations are generally transfused with very large volumes of blood products and our recent pilot study supports the possibility that transfusion-related EBV infection can be transmitted to pediatric hematopoietic stem cell (HSCT) recipients (Trottier et al, 2012). The aim of this study is to analyse the risk of EBV transmission through blood product transfusion in pediatric allogeneic HSCT patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoproliferative Disorders | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Determining the source of EBV in severe EBV infections | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Measure of the risk of EBV infection in HSCT pediatric recipients from blood products transfusions (red blood cells, platelets, plasma) by EBV PCR and serology testing
- timeFrame
- 1 month before transplantation to 1 year post-transplantation
- description
- EBV PCR and serology testing every 1-2 weeks until hospital discharge and at follow-up visit thereafter.
Secondary outcomes (3)
- measure
- Incidence of post-transplant EBV infection in allogeneic HSCT pediatric recipients stratified according to the EBV serostatus of the patient and the EBV status of the graft
- timeFrame
- 1 month before transplantation to 1 year post-transplantation
- description
- Surveillance for PTLD and other EBV complications
- measure
- Incidence of "high or increasing viral load EBV infection and PTLD" in allogeneic HSCT pediatric recipients stratified according to the EBV serostatus of the patient and the EBV status of the graft
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * patients receiving allogeneic HSCT (marrow, cord-blood, and peripheral blood stem cells) * age below 21 years * first HSCT Exclusion Criteria: \-
References
Publications (2)
- BACKGROUNDTrottier H, Buteau C, Robitaille N, Duval M, Tucci M, Lacroix J, Alfieri C. Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children. Transfusion. 2012 Dec;52(12):2653-63. doi: 10.1111/j.1537-2995.2012.03611.x. Epub 2012 Mar 15. PMID 22420319
- BACKGROUNDAlfieri C, Tanner J, Carpentier L, Perpete C, Savoie A, Paradis K, Delage G, Joncas J. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood. 1996 Jan 15;87(2):812-7. PMID 8555507